Global Depression Therapeutics Market, By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Trends, Analysis and Forecast till 2029

Report Code: PMI2618 | Publish Date: December 2023 | No. of Pages: 168

Global Depression Therapeutics Market By Overview

Depression is serious mood disorder characterized by persistent low mood and feeling of sadness and loss of interest. Accurate diagnosis of depression ensure further safe and effective treatment. Drug medication, psychotherapy or combination of both treatments is  most preferred treatment modality in the management of depression. Antidepressants are medicines that treat depression. Antidepressants include diverse range of drug categories which mainly includes selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and serotonin receptor modulators (SRMs).

 

Global Depression Therapeutics Market By Dynamics

Growing cases of mental disorders including depression and anxiety owing to changing lifestyle, increasing work pressure, trauma, and genetic factors are factors restraining growth of the global depression therapeutics market.

Incresing numbers of clinical trial studies currently undergoing for the treatment of depression by various key players in the market, is expected to offer lucrative growth opportunities in near future. For instance, in December 2017, Sage Therapeutics: a clinical –stage biopharmaceutical company developing the novel medicines for the treatment of central nervous system (CNS) disorders reports positive result from its phase II clinical trial of SAGE-217 in the treatment of patients with moderate to severe major depression disorder (MDD).

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Depression Therapeutics Market By Segmentation

The global depression therapeutics market has been segmented on the basis of drug type, distribution channel, and region.

On the basis of drug type, depression therapeutics market is segmented into Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and others. Distribution channel of depression therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, andAfrica.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Global Depression Therapeutics Market By Key Players

The key players operating in the global depression therapeutics market includes Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd., and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.

Global Depression Therapeutics Market By Table of Contents

Research Objective and Assumption

  • Preface
  • Research Objectives
  • Study Scope
  • Years Considered for the study
  • Assumptions
  • Abbreviations

Research Methodology

  • Research data
  • Primary Data
    • Primary Interviews
    • Primary Breakdown
    • Key data from Primary Sources
    • Key Thickness Insights
  • Secondary Data
    • Major Secondary Sources
    • Secondary Sources
  • Market Estimation
  • Top-Down Approach
    • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
  • Bottom-Up Approach
    • Approach for estimating market share by Bottom-up Analysis (Demand Side)
  • Market Breakdown and Data Triangulation
  • Research Assumptions

Market Preview

  • Executive Summary
  • Key Findings—Global Outlook for medical carts Strategies
    • Key Questions this Study will Answer
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channe
    • Market Snippet, By Region
  • Opportunity Map Analysis
  • Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restrains
    • Market Opportunities
    • Market Trends
  • DR Impact Analysis
  • PEST Analysis
  • Porter’s Five Forces Analysis
  • Opportunity Orbit
  • Market Investment Feasibility Index
  • Macroeconomic Factor Analysis

Depression Therapeutics Market, By Drug Type, Forecast Period up to 10 Years, (US$ Bn)

  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Depression Therapeutics Market, By Distribution Channe, Forecast Period up to 10 Years, (US$ Bn)

  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Hospital Pharmacy
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Retail Pharmacy
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Online Pharmacy
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Depression Therapeutics Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Regional Trends
  • North America
    • Market Size and Forecast (US$ Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Distribution Channe, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
      • U.S.
      • Canada
  • Europe
    • Market Size and Forecast (US$ Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Distribution Channe, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
      • UK
      • France
      • Germany
      • Russia
      • Italy
      • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast (US$ Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Distribution Channe, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
      • India
      • Japan
      • South Korea
      • China
      • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast (US$ Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Distribution Channe, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
  • Brazil
  • Mexico
  • Rest of Latin America

 

  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Drug Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Distribution Channe, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East

Competitive Landscape

  • Heat Map Analysis
  • Market Presence and Specificity Analysis

Company Profiles

  • Pfizer, Inc
    •   Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca Plc
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Allergan Plc
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline Plc
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Intellipharmaceutics International, Inc
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Takeda Pharmaceutical Company Limited
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • H.Lundbeck A/S
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Otsuka Holdings Co.,Ltd.
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Apotex, Inc
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Shionogi & Co. Ltd
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Zhejiang Hua Hai Pharmaceutical Co
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
    •  Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

Global Depression Therapeutics Market is segmented By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Growing cases of mental disorders including depression and anxiety owing to changing lifestyle, increasing work pressure, trauma, and genetic factors are factors restraining growth of the global depression therapeutics market.

Depression Therapeutics Market accounted for US$ 13.7 billion in 2020 and is estimated to be US$ 17.49 billion by 2030 and is anticipated to register a CAGR of 3.0%.

Depression Therapeutics Market is segmented by Drug type, Distribution, and region.

the development of novel therapeutic approaches, increasing research in gene therapy, and advancements in precision medicine, presenting significant opportunities in the global Sandhoff Disease Treatment Market.

the need for effective treatments for rare genetic disorders, advancements in medical research, increasing awareness and diagnosis of Sandhoff disease, and collaborations between pharmaceutical companies and research institutions.

North America, Europe, and Asia-Pacific are likely to be key regions, but the situation is dynamic, and it's advisable to refer to the latest reports for the most current information.

The key players operating in the global depression therapeutics market includes Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd., and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.